European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

NCT07545759

ClinicalTrials.gov

Trial ID
T-ctgov-NCT07545759
Registry
ClinicalTrials.gov
NCT number
NCT07545759
CTIS number
2025-524973-17-00
Asset
brenipatide (LY3537031)
Sponsor, as registered
Eli Lilly and Company
Phase
PHASE2
Indication
Irritable Bowel Syndrome; Diarrhea
Status
RECRUITING
Start date
2026-05-06
Primary completion
2027-09
Registered countries
Belgium, Canada, China, Germany, Japan, Mexico, Poland, Spain, United Kingdom, United States
Sites
89

The sponsor's registered location list, which states intent rather than approval.

clinicaltrials.govctgov registryverified 2026-09-28

Notes on the record

Fields read from the ClinicalTrials.gov v2 API record. countries is the distinct country list across all registered locations; site_count is the number of location entries, which counts a country once per site, not once per country. Added 2026-09-28 from the Issue 16 collection: the record was updated in the 21 to 28 September window (LastUpdatePostDate 2026-09-22). Companion CTIS record 2025-524973-17-00 is already in the file.

Company

Through brenipatide (LY3537031): Lilly

Cited in

Issues quoting NCT07545759 in their own text.